VANI—(+313%)—reports preclinical data for Exenatide implant: https://www.businesswire.com/news/home/20240228342864/en Everyone is chasing the obesity market. Caveat emptor. VANI (f/k/a Nano Precision Medicine) is the result of a 2022 reverse-merger (#msg-169535742).